Difference between revisions of "Dexrazoxane (Zinecard)"
m |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 8: | Line 8: | ||
==Efficacy references== | ==Efficacy references== | ||
<!-- Results from this manuscript have been presented at the American Society of Clinical Oncology Scientific Sessions, Chicago, IL, June 1-5, 2012, and at the American Society of Pediatric Hematology/Oncology Annual Meeting, Cincinnati, OH May 15-17, 2008. --> | <!-- Results from this manuscript have been presented at the American Society of Clinical Oncology Scientific Sessions, Chicago, IL, June 1-5, 2012, and at the American Society of Pediatric Hematology/Oncology Annual Meeting, Cincinnati, OH May 15-17, 2008. --> | ||
| − | # Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2015 Dec 23. [Epub ahead of print] [http://jco.ascopubs.org/content/34/8/854.full link to original article] [ | + | # Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2015 Dec 23. [Epub ahead of print] [http://jco.ascopubs.org/content/34/8/854.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26700126 PubMed] |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 02:19, 2 December 2016
General information
Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of anthracycline extravasation.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Efficacy references
- Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2015 Dec 23. [Epub ahead of print] link to original article PubMed
Patient drug information
- Dexrazoxane (Zinecard) patient drug information (Chemocare)[6]
- Dexrazoxane (Zinecard) patient drug information (UpToDate)[7]
Also known as
Cardioxane, Dexrazoxane hydrochloride, or Totect.
References
- ↑ 1.0 1.1 Dexrazoxane (Zinecard) package insert
- ↑ Dexrazoxane (Zinecard) package insert (locally hosted backup)
- ↑ Zinecard manufacturer's website
- ↑ Dexrazoxane (Totect) package insert
- ↑ Totect manufacturer's website
- ↑ Dexrazoxane (Zinecard) patient drug information (Chemocare)
- ↑ Dexrazoxane (Zinecard) patient drug information (UpToDate)